Moyamoya Disease Clinical Trial
— RIC-IMDOfficial title:
Safety and Efficacy of Remote Ischemic Conditioning Combined Encephaloduroarteriosynangiosis(EDAS)on Ischemic Moyamoya Disease: A Prospective, Randomized, Controlled Study
NCT number | NCT04917003 |
Other study ID # | RIC-IMD |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 15, 2021 |
Est. completion date | June 30, 2022 |
Encephaloduroarteriosynangiosis (EDAS) is widely used as an indirect technique for treatment of moyamoya disease. Nevertheless, this indirect surgery tends to establish insufficient collateral circulation in most adult MMD patients. Nowadays, there is a lack of adjuvant therapies for improving collateral circulation induced by indirect revascularization. This study aims to explore whether remote ischemic conditioning can improve the collateral circulation after indirect revascularization.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Subjects who were diagnosed as moyamoya disease by the diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012. 2. Suzuki stage: 2-5 stage 3. Age: between 18 and 65 years old 4. Subjects present with ischemic stroke or transient ischemic attack. 5. Subjects who plan to accept the first EDAS surgery. 6. Informed consent obtained from patient or patient's surrogate Exclusion Criteria: 1. Acute ischemic stroke occurred within one month. 2. Suffered Intracranial hemorrhage before 3. Subjects with large infarction spread widely over the territory of a main arterial trunk 4. Aneurysms in the main arterial trunk 5. Severe cardiac diseases like atrial fibrillation,valvular disease,heart failure, infective endocarditis and so on. 6. Malignant tumors or severe disordered function of the heart, lung, liver or kidney. 7. Severe hemostatic disorder or severe coagulation dysfunction. 8. Uncontrolled diabetes mellitus with a serum fasting blood glucose level>300 mg/dL, or requires insulin; hypertension with a systolic blood pressure over 180 mmHg or a diastolic blood pressure over 110 mmHg. 9. Severe injury on upper limbs. 10. Pregnant or lactating women. 11. Life expectancy is less than 3 years. 12. Patients who are not suitable for this trial considered by researchers for other reasons |
Country | Name | City | State |
---|---|---|---|
China | The 307th Hospital of the Chinese People's Liberation Army | Beijing |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University | Beijing 302 Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | rCBF changed ratio at operative side | Cerebral blood flow will be evaluated by dynamic susceptibility contrast-MRI examination,and relative cerebral blood flow(rCBF) changed ratio will be calculated by the formula: (rCBF in MCA territory/rCBF in cerebellum after treatment - rCBF in MCA territory/rCBF in cerebellum before treatment )/ rCBF in MCA territory/rCBF in cerebellum before treatment (the operative side). The higher value of rCBF improvement ratio means better imaging outcome. | From baseline to 3 months. | |
Secondary | the change of TTP delay at operative side | Time to peak(TTP) will be evaluated by dynamic susceptibility contrast-MRI examination. The improvement of TTP delay at operative side will be calculated by the formula: the change of TTP delay =TTP delay in MCA territory before treatment - TTP delay in MCA territory after treatment (the operative side). The higher value means better imaging outcome. | From baseline to 3 months. | |
Secondary | rCBF changed ratio at non-operative side | Cerebral blood flow will be evaluated by dynamic susceptibility contrast-MRI examination,and relative cerebral blood flow(rCBF) changed ratio will be calculated by the formula: (rCBF in MCA territory/rCBF in cerebellum after treatment - rCBF in MCA territory/rCBF in cerebellum before treatment )/ rCBF in MCA territory/rCBF in cerebellum before treatment (the non-operative side). The higher value of rCBF improvement ratio means better imaging outcome. | From baseline to 3 months. | |
Secondary | the change of TTP delay at non-operative side | Time to peak(TTP) will be evaluated by dynamic susceptibility contrast-MRI examination. The improvement of TTP delay at non-operative side will be calculated by the formula: Improvement of TTP delay =TTP delay in MCA territory before treatment - TTP delay in MCA territory after treatment (the non-operative side). The higher value means better imaging outcome. | From baseline to 3 months. | |
Secondary | Incidence of major adverse cerebral event ( MACE) | MACE contains ischemic or hemorrhagic stroke, crescendo TIAs evaluated by registered Neurologists. | From baseline to 3 months. | |
Secondary | The change of luminal area of superficial temporal artery | The luminal area of STA can reflect the angiogenesis induced by EDAS to some extent, and it will be measured by TOF-MRA. | From baseline to 3 months. | |
Secondary | The degree of the collaterals from superficial temporal artery | The degree of the collaterals from superficial temporal artery will be evaluated by Transcranial Doppler ultrasound performed by an experienced technician. 0 for no collaterals from STA, 1 for little collaterals from STA, 2 for good collaterals from STA . | From baseline to 3 months. | |
Secondary | Volume of regions with hyperintense signal | Volume of regions with hyperintense signal where the maximum dimension should be larger than 8mm will be measured at axial T2, fluid-attenuated inversion recovery. | From baseline to 3 months. | |
Secondary | Number of regions with hyperintense signal | Number of regions with hyperintense signal will be counted at axial T2, fluid-attenuated inversion recovery. | From baseline to 3 months. | |
Secondary | RIC related Adverse events | Adverse events related to RIC treatment, such as local edema, erythema, skin lesions of the arms. | From baseline to 3 months. | |
Secondary | Flow velocity of superficial temporal artery at operative side | Flow velocity of superficial temporal artery at operative side will be evaluated by Transcranial Doppler ultrasound performed by an experienced technician. | From baseline to 3 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03785171 -
Predicative Value of Multimodal MRI in Moyamoya Disease
|
||
Recruiting |
NCT05619068 -
The Evolution and Prognosis of Moyamoya Disease
|
||
Recruiting |
NCT03613701 -
Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease
|
||
Recruiting |
NCT06041659 -
Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
|
||
Not yet recruiting |
NCT06051552 -
Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery
|
||
Suspended |
NCT04064658 -
Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients
|
N/A | |
Recruiting |
NCT03627975 -
Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease
|
N/A | |
Not yet recruiting |
NCT06330818 -
Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients
|
N/A | |
Recruiting |
NCT05332756 -
Long-term Outcomes of Conservative Management in Patients With Moyamoya Disease and Their First-degree Relatives (LAMORA)
|
||
Recruiting |
NCT04890782 -
Gut Microbiota in Patients With Moyamoya Disease
|
||
Completed |
NCT03162588 -
Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya
|
Phase 1/Phase 2 | |
Completed |
NCT03072914 -
Effects of Remote Ischemic Preconditioning With Postconditioning on Neurologic Outcome
|
N/A | |
Recruiting |
NCT02305407 -
Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery
|
N/A | |
Completed |
NCT04012268 -
The Safety and Efficacy of RIC on Adult Moyamoya Disease
|
N/A | |
Not yet recruiting |
NCT04205578 -
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
|
Phase 3 | |
Recruiting |
NCT02982135 -
Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease
|
N/A | |
Recruiting |
NCT02074111 -
Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke
|
N/A | |
Recruiting |
NCT04696094 -
The Role of m6A RNA Modification in Moyamoya Disease
|
||
Completed |
NCT04906564 -
RNF213 Variants and Collateral Vessels in Moyamoya Disease
|
||
Recruiting |
NCT05961748 -
Registry of Multicenter Brain-Heart Comorbidity in China
|